$1.17
-0.04 (-3.31%)
Open$1.21
Previous Close$1.21
Day High$1.23
Day Low$1.13
52W High$2.45
52W Low$0.78
Volume—
Avg Volume1.63M
Market Cap17.86M
P/E Ratio—
EPS$-0.80
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+2,802.6% upside
Current
$1.17
$1.17
Target
$33.96
$33.96
$19.62
$33.96 avg
$35.69
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 227.0K | 590.4K | 1.55M |
| Net Income | -31,155,262 | -72,925,190 | 361.3K |
| Profit Margin | -13,700.0% | -13,015.0% | 23.4% |
| EBITDA | -30,891,690 | -76,325,371 | 534.5K |
| Free Cash Flow | — | — | 193.8K |
| Rev Growth | -61.6% | -61.6% | +15.5% |
| Debt/Equity | — | — | 1.22 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.53 | -1.09% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $361.16 | +0.17% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.13 | -0.16% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $494.74 | -0.98% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $628.06 | -0.59% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $297.43 | +1.33% | 69.3 | 39.97B |